A Study Of Early Markers Of Choroidal Neovascularization

Terminated

• Conditions: Choroidal Neovascularization (CNV); Age-related Macular Degeneration (AMD); Early Markers
• Interventions: Other: no drug

• Registration Number: NCT00902785
• Lead Sponsor: Pfizer

Brief Summary

Identify early markers of choroidal neovascularization (CNV) in the fellow eye of a patient with CNV in the other eye due to age-related macular degeneration with the expectation of being able to identify patients in need of intervention.

Detailed Description

CNV in one eye and dry AMD in the other

Study Timeline

• Study Start: 2008-03
• Study First Submitted: 2009-05-13
• Study First Submitted QC: 2009-05-14
• Study First Posted: 2009-05-15
• Primary Completion: 2010-05
• Study Completion: 2010-05
• Status Verified: 2010-11
• Last Update Submitted: 2010-11-09
• Last Update Posted: 2010-11-10

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Sub-, extra- or juxta-foveal choroidal neovascularization (CNV) or macular scar due to AMD in the non-study eye.
• No CNV or geographic atrophy in the study eye.
• Best corrected visual acuity in the study eye of greater than 20/40 or better than 70 ETDRS letters.
• Sufficiently clear ocular media and adequate pupillary dilatation to permit good quality fundus imaging of the study eye.
• Subjects of either sex, aged 50 years.
• Evidence of a signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial.
• Willing and able to comply with scheduled visits, laboratory tests, and other trial procedures.

Exclusion Criteria

• Subjects presenting with any of the following will not be included in the study:
• Evidence of manifest CNV by FA, color photography or ICG angiography in the study eye.
• Any prior treatment for CNV to the study eye (excluding vitamins and AREDS formula).
• Significant media opacities, including cataract, which might interfere with visual acuity assessments, or fundus imaging in the study eye. Subjects should not be entered if there is likelihood that they will require cataract surgery within the following 2 years.
• Presence of other causes of choroidal neovascularization in the fellow eye, including pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial length of 25 mm or more), the ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, and multifocal choroiditis.
• Any progressive eye disease other than AMD (eg, glaucoma, diabetic retinopathy) in the study eye.
• Presence of subretinal hemorrhage, serous or hemorrhagic pigment epithelial detachments, subretinal fibrosis or pigment epithelial tears or rips in the study eye.
• Any medical condition that would interfere with the patient's ability to complete the trial.
• Concurrent enrollment in any other observational or interventional clinical study.
• Any treatment with an ocular or systemic investigational agent in the past 60 days for any medical condition.
• Known serious allergies to the dye used in fluorescein angiography or ICG.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
no drug	no drug	no drug

Primary Outcome Measures

Name	Time	Method
Identify the sequence of change in the chorioretinal interface during the development of CNV and the progression from dry to neovascular AMD.	2 years

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇬🇧 Belfast, United Kingdom